医疗辅助死亡(MAiD)供肝:临床结局与DCD、DBD供肝的比较
该研究比较了2016至2021年多伦多总医院接受MAiD、DCD和DBD供肝移植受者的结局。MAiD组胆道并发症发生率最高(18.2% vs DCD 14.2% vs DBD 5.8%,P=0.008),但三组1年和3年患者及移植物生存率无显著差异。结果表明MAiD供肝可安全用于肝移植,短期和长期结局与其他供体类型相当。
要点
- MAiD供肝移植后胆道并发症发生率高于DCD和DBD供肝(18.2% vs 14.2% vs 5.8%,P=0.008)
- 三组1年和3年患者生存率及移植物生存率均无显著差异
- MAiD供肝可安全用于肝移植,但需注意胆道并发症风险
核心结论
- MAiD供肝移植后胆道并发症发生率较高,但短期和长期移植物结局与DCD和DBD供肝无显著差异,表明MAiD供肝可安全用于肝移植。
研究设计与样本
- 回顾性队列研究,纳入2016至2021年多伦多总医院所有接受 deceased donor 肝移植的患者,比较DBD(n=719)、DCD(n=77)和MAiD(n=11)三组的受者围术期和术后变量及供体生理变量。
主要发现
- 总体胆道并发症发生率为6.9%(n=56),最常见为胆道狭窄(n=55,6.8%),MAiD组胆道并发症发生率最高(18.2%),DCD组为14.2%,DBD组为5.8%(P=0.008)。
- 三组1年患者生存率分别为98.4%(DBD)、96.4%(DCD)、100%(MAiD),3年患者生存率分别为89.3%、88.7%、100%(P=0.56)。
- 三组1年移植物生存率分别为96.2%、95.2%、100%,3年移植物生存率分别为92.5%、91%、100%(P=0.37)。
关键数值与推荐
- MAiD组胆道并发症发生率18.2%,DCD组14.2%,DBD组5.8%,P=0.008。
- 1年患者生存率:DBD 98.4%,DCD 96.4%,MAiD 100%;3年患者生存率:DBD 89.3%,DCD 88.7%,MAiD 100%(P=0.56)。
- 1年移植物生存率:DBD 96.2%,DCD 95.2%,MAiD 100%;3年移植物生存率:DBD 92.5%,DCD 91%,MAiD 100%(P=0.37)。
临床怎么用
- MAiD供肝可作为肝移植的供体来源,但需警惕较高的胆道并发症风险,加强术后胆道监测与管理。
局限性
- MAiD组样本量较小(n=11),可能影响统计效能和结果的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report the clinical outcomes of liver transplants from donors after medical assistance in dying (MAiD) versus donors after cardiac death (DCD) and deceased brain death (DBD). SUMMARY BACKGROUND DATA: In North America, the number of patients needing liver transplants exceeds the number of available donors. In 2016, MAiD was legalized in Canada. METHODS: All patients undergoing deceased donor liver transplantation at Toronto General Hospital between 2016 and 2021 were included in the study. Recipient perioperative and postoperative variables and donor physiological variables were compared among 3 groups. RESULTS: Eight hundred seven patients underwent deceased donor liver transplantation during the study period, including DBD (n=719; 89%), DCD (n=77; 9.5%), and MAiD (n=11; 1.4%). The overall incidence of biliary complications was 6.9% (n=56), the most common being strictures (n=55;6.8%), highest among the MAiD recipients [5.8% (DBD) vs. 14.2% (DCD) vs. 18.2% (MAiD); P =0.008]. There was no significant difference in 1 year (98.4% vs. 96.4% vs. 100%) and 3-year (89.3% vs. 88.7% vs. 100%) ( P =0.56) patient survival among the 3 groups. The 1- and 3- year graft survival rates were comparable (96.2% vs. 95.2% vs. 100% and 92.5% vs. 91% vs. 100%; P =0.37). CONCLUSION: With expected physiological hemodynamic challenges among MAiD and DCD compared with DBD donors, a higher rate of biliary complications was observed in MAiD donors, with no significant difference noted in short-and long-term graft outcomes among the 3 groups. While ethical challenges persist, good initial results suggest that MAiD donors can be safely used in liver transplantation, with results comparable with other established forms of donation.
引用
- Ray S, Torres-Hernandez A, Bleszynski MS, et al. Medical Assistance in Dying (MAiD) as a Source of Liver Grafts: Honouring the Ultimate Gift. Ann Surg. 2022. PMID: 36515405. doi:10.1097/SLA.0000000000005775
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。